交易 Arvinas Inc - ARVN
Arvinas, Inc., a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. Its lead product candidates are ARV-110, a proteolysis targeting chimera (PROTAC) protein degrader that is in phase I clinical trial targeting the androgen receptor (AR) protein for the treatment of men with metastatic castration-resistant prostate cancer; and ARV-471, a PROTAC protein degrader targeting the estrogen receptor protein for the treatment of patients with metastatic ER positive/HER2 negative breast cancer. The company has collaborations with Pfizer Inc., Genentech, Inc., F. Hoffman-La Roche Ltd., Bayer AG, and Insilico Medicine, Inc. Arvinas, Inc. was incorporated in 2013 and is based in New Haven, Connecticut.最新股票文章
Uber Technologies 股价预测：裁减 3,300 个职位，拓展机器人出租车业务
Uber 正进行重组，裁减约 3,300 个职位，同时在机器人出租车市场竞争加剧之际，扩大自动驾驶汽车合作关系。本文整理第三方对 UBER 的股价目标及技术分析。过往表现并非未来业绩的可靠指标。
10:57, 2 十月 2026
微软股价预测 | Azure 营收与财报分部调整
微软是一家美国科技公司。2026 财年，Azure 营收达 1,019 亿美元，公司亦宣布将于 2027 财年采用新的财报分部架构。了解第三方 MSFT 目标价及技术分析。过往表现并非未来业绩的可靠指标。
14:45, 25 九月 2026
NVIDIA 股价预测 | 收购 Hugging Face
NVIDIA 是一家美国半导体公司，于 2026 年 9 月同意以约 129.3 亿美元收购 AI 平台 Hugging Face。了解第三方 NVDA 目标价及技术分析。过往表现并非未来业绩的可靠指标。
12:23, 25 九月 2026
评分与评论
评分与评论
